TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35169280
Drug: Febuxostat treatment
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat treatment group
Study: 35793182
Drug: PKP +
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PKP + LAI (lidocaine + triamcinolone acetonide injections)
Study: 34571091
Drug: TPF induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF induction chemotherapy (75 mg/m2 cisplatin and 75 mg/m2 docetaxel on day 1 and 750 mg/m2 fluorouracil from the first to the fifth day)
Study: 34491123
Drug: Zanubrutinib (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanubrutinib (320 mg once daily or 160 mg twice daily)
Study: 33617042
Drug: CJM112 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: CJM112 15 mg, 50 mg, and 150 mg subcutaneous (s.c.)
Study: 33617042
Drug: CJM112 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: CJM112 450 mg subcutaneous (s.c.)
Study: 33617042
Drug: CJM112 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: CJM112 150 mg high frequency
Study: 33253089
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg subcutaneous (s.c.)
Study: 34936273
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aerosol (125 μg per inhalation, twice a day)
Study: 32816578
Drug: L-Carnitine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Carnitine (1000 mg/day)
Study: 32389396
Drug: Analgesics provided
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics provided
Study: 32214296
Drug: Hyalase +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyalase + 10 mL saline solution injection
Study: 32214296
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL saline solution only
Study: 33267591
Drug: Almagate (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almagate (1.5 g)
Study: 35773711
Drug: Phasic muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phasic muscle therapy protocol using the StimaWELL 120MTRS system
Study: 35773711
Drug: Combined muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined muscle therapy protocol (phasic + tonic) using the StimaWELL 120MTRS system
Study: 33200808
Drug: PHP (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHP (in subgroup analysis excluding antithrombotic agents)
Study: 33200808
Drug: Control (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (in subgroup analysis excluding antithrombotic agents)
Study: 32078948
Drug: Peginterferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon beta‐1a 125 mcg every 2 weeks
Study: 33691647
Drug: Therap-i module
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therap-i module integrated into treatment as usual (TAU) for depression
Study: 33104761
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) and psychopharmacology within a collaborative care model
Study: 32448335
Drug: Apatinib mesylate
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib mesylate (500 mg, once daily) combined with vinorelbine (40 mg, thrice a week)
Study: 32448335
Drug: Vinorelbine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine alone (40 mg, thrice a week)
Study: 33515781
Drug: TAKE IT
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAKE IT intervention (multifaceted medication adherence monitoring strategy)
Study: 34022839
Drug: Food literacy
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food literacy constructs including nutrition knowledge, food preparation and cooking skills, self-efficacy and behaviours, food waste knowledge and behaviours, and food production knowledge.
Study: 35925872
Drug: Individualized nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized nutritional interventions with normoproteic diets (1.0 g/kg) after 60 days of KTx
Study: 35595091
Drug: Empagliflozin 10mg
Normalized name: EMPAGLIFLOZIN 10MG TAB
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 10mg daily in addition to standard care
Study: 32668114
Drug: Accelerated strategy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated strategy of renal-replacement therapy (initiated within 12 hours)
Study: 32668114
Drug: Standard strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard strategy of renal-replacement therapy (initiated after 72 hours or conventional indications)
Study: 32668114
Drug: Accelerated strategy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated strategy of renal-replacement therapy
Study: 32668114
Drug: Standard strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard strategy of renal-replacement therapy
Study: 36464237
Drug: 2 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Hz electroacupuncture treatment
Study: 36464237
Drug: 20/100 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20/100 Hz electroacupuncture treatment
Study: 34134645
Drug: Chronic anticoagulation
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic anticoagulation therapy
Study: 34134645
Drug: No anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulation therapy (Control)
Study: 33354803
Drug: Improvac® (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improvac® (two doses, 28 days apart)
Study: 32456572
Drug: Hemp Oil
Normalized name: HEMP OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemp Oil Extract (60 mg/d, 15 mg hemp-derived CBD)
Study: 33620619
Drug: Adjunctive posterior
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive posterior wall isolation
Study: 36459243
Drug: BNT162b2 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 mRNA vaccine
Study: 34836429
Drug: HAPIFED (integrates
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAPIFED (integrates cognitive behavioural therapy with body weight loss therapy)
Study: 34836429
Drug: CBT‐E (cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT‐E (cognitive behavioural therapy with extended sessions alone)
Study: 33356033
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors in addition to baseline treatment (Group A)
Study: 33356033
Drug: Baseline treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline treatment or other medications as needed (Group B)
Study: 36179736
Drug: Oral fexinidazole
Normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fexinidazole
Study: 34969771
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg BMS-986278
Study: 34969771
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg BMS-986278
Study: 32205595
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment without a preestablished routine
Study: 33845761
Drug: Dexmedetomidine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.6 µg/kg/h)
Study: 34981180
Drug: Topiramate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (200 mg/day for 5 weeks)
Study: 32007328
Drug: Administration, workload,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration, workload, relationships with colleagues, work itself, remuneration and benefits
Study: 33829803
Drug: FORNET (Narrative
Approvals — FDA: no, EMA: no, PMDA: no
Description: FORNET (Narrative Exposure Therapy for Forensic Offender Rehabilitation)
Study: 33158948
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance index (IRI)
Study: 34730461
Drug: Dried egg
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried egg white protein supplementation (20 g protein daily)
Study: 34730461
Drug: Isocaloric maltodextrin
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric maltodextrin supplement
Study: 35356054
Drug: 30-minutes of
Normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30-minutes of daily morning bright white light (BWL)
Study: 34713539
Drug: Subantibiotic dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantibiotic dose oral doxycycline 40 mg modified-release capsules once daily (SDD40)
Study: 33885773
Drug: Default dispense
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Default dispense quantity of 10 tablets
Study: 34325109
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m2 followed by trabectedin 1.1 mg/m2 as a 3‐h infusion on day 1 and pegfilgrastim on day 2, every 3 weeks, up to six cycles
Study: 34674896
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser therapy (Ga-As super pulsed laser therapy)
Study: 34674896
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser therapy (inactive laser)
Study: 34064427
Drug: Fascia Iliaca
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascia Iliaca Compartment Block (FICB) with 0.375% ropivacaine, nonopioid analgesics (paracetamol, metamizole, pregabalin), and oxycodone as rescue analgesia
Study: 34064427
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous analgesia with FICB
Study: 36619342
Drug: Big patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Big patch (30,000 IU cholecalciferol)
Study: 36619342
Drug: Small patch
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small patch (30,000 IU cholecalciferol)
Study: 36619342
Drug: Both patches
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both patches (30,000 IU cholecalciferol)
Study: 32308680
Drug: Insulin administration
Normalized name: insulin administration supplies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin administration
Study: 34635374
Drug: Biological contamination
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological contamination
Study: 35174663
Drug: Leucine 2.5
Normalized name: isoleucine 2.52 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucine 2.5 g thrice daily
Study: 35174663
Drug: Meta-analysis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meta-analysis of ACE inhibitors/ARBs
Study: 32594675
Drug: Triple chronotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple chronotherapy (combined total sleep deprivation, light therapy, and sleep phase advance) add-on to standard pharmacological treatment
Study: 35474627
Drug: Inpatient multimodal
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient multimodal treatment (IMT)
Study: 33865471
Drug: 3-monthly ART
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3-monthly ART dispensing
Study: 33865471
Drug: 6-monthly ART
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6-monthly ART dispensing
Study: 34334898
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 400 mg twice on day 1, then 400 mg once daily from day 2 to day 5
Study: 34372928
Drug: Nutricia™ preOp®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutricia™ preOp® (400 mL) administered to the pre-op group after 10 hours of fasting.
Study: 34936159
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both methods (TC-APP)
Study: 32618267
Drug: Dihydroartemisinin-piperaquine (DHAp)
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (DHAp) administered during MDA/fMDA
Study: 35120577
Drug: High single
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High single dose of vitamin D (140,000 IU) followed by treatment as usual (TAU)
Study: 35120577
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + treatment as usual (TAU)
Study: 33828219
Drug: Exploratory cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exploratory cohort patients measuring upper vertical lung length (uVLL), lower vertical lung length (lVLL), total vertical lung length (tVLL), and l/uVLL ratio on chest X-rays.
Study: 33828219
Drug: l/uVLL ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: l/uVLL ratio measurement
Study: 33899607
Drug: Commonly used
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commonly used generalized linear models (e.g., logistic regression, Poisson regression)
Study: 34909972
Drug: Oral dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dydrogesterone 40 mg/day
Study: 34909972
Drug: Micronized vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized vaginal progesterone 800 mg/day
Study: 33399242
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy without chemotherapy
Study: 36859316
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl solution (control)
Study: 35475947
Drug: 6 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 sessions of treatment
Study: 35475947
Drug: 12 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 sessions of treatment
Study: 33309893
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl solution (placebo)
Study: 32412157
Drug: Nivolumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab treatment <2 years
Study: 32412157
Drug: Nivolumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab treatment for 2 years
Study: 32412157
Drug: Nivolumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab treatment >2 years
Study: 32412157
Drug: Nivolumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab treatment (all groups)
Study: 33974972
Drug: Standard intraprocedural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intraprocedural local anesthetic, intra‐arterial lidocaine, and intravenous analgesia (Control)
Study: 32522320
Drug: Modified atraumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified atraumatic restorative treatment (mART)
Study: 35987550
Drug: Compound intervention
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound intervention (IP + WBE), n=87
Study: 32208168
Drug: INO-5150 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: INO-5150 (2 mg)
Study: 32208168
Drug: INO-5150 (8.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: INO-5150 (8.5 mg)
Study: 32208168
Drug: INO-5150 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: INO-5150 (2 mg) + INO-9012 (1 mg)
Study: 32208168
Drug: INO-5150 (8.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: INO-5150 (8.5 mg) + INO-9012 (1 mg)
Study: 36349571
Drug: PEEP titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEEP titration to the lowest driving pressure
Study: 32591439
Drug: Intensive hypertension
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive hypertension treatment (targeting systolic BP <120 mm Hg)
Study: 32591439
Drug: Standard hypertension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hypertension treatment (targeting systolic BP <140 mm Hg)
Study: 32591439
Drug: Incident eGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incident eGFR <60 ml/min per 1.73 m2
Study: 32591439
Drug: Baseline and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline and incident urinary ACR ≥30 mg/g
Study: 34657407
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of cardiovascular drugs (aspirin, antihypertensives, statins)
Study: 32448722
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch supplementation (35 g/d)
Study: 35921606
Drug: New cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: New cancer drugs
Study: 34393120
Drug: 2.5% lidocaine/2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% lidocaine/2.5% prilocaine topical anesthetic
Study: 34393120
Drug: Injection anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection anesthetic
Study: 34393120
Drug: L/P topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: L/P topical anesthetic
Study: 35466800
Drug: Counselling program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counselling program based on cognitive behavioural therapy (16 sessions)
Study: 32213303
Drug: Plasma suPAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma suPAR level above 3.70 ng mL-1
Study: 34643947
Drug: Histology-tailored (HT)
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histology-tailored (HT) chemotherapy
Study: 33094898
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and passive muscle stretching exercises
Study: 33017854
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (GPT)
Study: 33264200
Drug: Treatment-as-usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU) group (n = 30)
Study: 33823924
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ESPB) with 0.375% ropivacaine 0.4 ml/kg
Study: 33823924
Drug: Thoracic paravertebral
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic paravertebral block (TPVB) with 0.375% ropivacaine 0.4 ml/kg
Study: 35817286
Drug: Methylprednisolone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (60 mg/day in two divided doses)
Study: 32272777
Drug: LF-containing yogurt
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LF-containing yogurt (100 mg/day)
Study: 33876660
Drug: Song of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Song of Life music therapy intervention
Study: 34225757
Drug: First trimester
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First trimester PM2.5 concentration increase (20.1 µg/m3)
Study: 33136069
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics after UTI
Study: 35924869
Drug: MedMon (medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: MedMon (medication monitoring control)
Study: 32725244
Drug: Stepwise approach
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepwise approach including 6-month lifestyle modification curriculum plus metformin
Study: 36501086
Drug: Ferric Carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric Carboxymaltose (FCM) 500 mg IV infusion, given at time 0 and repeated after 4 weeks
Study: 36501086
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 mL of saline given i.v. in 10 min), n = 32
Study: 34836336
Drug: Cooked coix
Normalized name: egg shell, cooked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooked coix seed (160 g per day) for 7 days
Study: 33966521
Drug: Diuretic adjustment
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic adjustment algorithm (DAA) with telephone follow-ups for 30 days
Study: 33966521
Drug: Diuretic adjustment
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic adjustment algorithm (DAA)
Study: 33966521
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) - diuretic dose adjusted by physician at baseline only
Study: 32846573
Drug: Mango juice
Normalized name: mango juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mango juice by-product (JBP) beverage (0.04 g·ml-1)
Study: 34674670
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ibuprofen 10 mg/kg
Study: 32173020
Drug: Canal preparation
Normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canal preparation using Protaper Next files until size X3
Study: 32173020
Drug: Canal preparation
Normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canal preparation using Protaper Next files until size X5